Courier Capital LLC Has $629,000 Stock Position in Sanofi $SNY

Courier Capital LLC trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 12.6% during the second quarter, Holdings Channel reports. The firm owned 13,012 shares of the company’s stock after selling 1,880 shares during the period. Courier Capital LLC’s holdings in Sanofi were worth $629,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in SNY. Ameritas Advisory Services LLC acquired a new stake in Sanofi during the second quarter valued at approximately $28,000. Accent Capital Management LLC acquired a new stake in Sanofi during the first quarter valued at approximately $29,000. Eastern Bank boosted its holdings in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sanofi during the first quarter valued at approximately $33,000. Finally, Golden State Wealth Management LLC boosted its holdings in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Barclays reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Sanofi in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Stock Performance

SNY stock opened at $49.22 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The company has a 50 day moving average price of $48.32 and a 200 day moving average price of $49.70. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The stock has a market capitalization of $120.86 billion, a PE ratio of 11.83, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter last year, the firm earned $1.73 EPS. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. Analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.